Brian Shimkus, MD
Medical Oncology · Georgetown, TXNPI 1730164591
Payments from drug & device makers
Across 1,321 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- EMD Serono, Inc.$3K
- Novartis$2K
- AstraZeneca$2K
- Pharmacosmos Therapeutics Inc.$2K
- Merck$1K
- plus $18K from 54 others
What the payments were for
- Consulting fees$2,6408%
- Speaking & faculty fees$1,6555%
- Food & beverage$26,06182%
- Education$8073%
- Other$4992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BAVENCIO$2,040
- Monoferric$1,500
- Tepmetko$500
- RYBREVANT$341
- CARVYKTI$341
- Erleada$236
- AKEEGA$236
- myRisk$168
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$165
- KEYTRUDA$100
How this compares
$31,662 in reported general payments places this provider in the 45th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 80 | $1,100,664 |
| RevlimidLenalidomide | 47 | $702,203 |
| XtandiEnzalutamide | 63 | $685,664 |
| PomalystPomalidomide | 24 | $515,710 |
| ImbruvicaIbrutinib | 28 | $450,329 |
| PromactaEltrombopag Olamine | 30 | $439,825 |
| CalquenceAcalabrutinib Maleate | 24 | $275,425 |
| VerzenioAbemaciclib | 14 | $177,550 |
| SprycelDasatinib | 11 | $176,413 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 45 | $170,238 |
| EliquisApixaban | 144 | $145,270 |
| Abiraterone Acetate | 39 | $138,932 |
| XareltoRivaroxaban | 90 | $106,042 |
| DopteletAvatrombopag Maleate | 19 | $105,528 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 32 | $103,941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $2,896 | $1,206,706170 claims |
| Bristol Myers SquibbRevlimid | $768 | $702,20347 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $1,315 | $692,12335 claims |
| Astellas Pharma US IncXtandi | $519 | $685,66463 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $123 | $450,32928 claims |
| NovartisPromacta | $1,921 | $439,82530 claims |
| PfizerOctagam, Eliquis | $1,303 | $315,508189 claims |
| AstraZenecaCalquence | $1,846 | $275,42524 claims |
| Lilly USA, LLCVerzenio | $511 | $177,55014 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $150 | $138,93239 claims |
| Dova PharmaceuticalsDoptelet | $95 | $105,52819 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $501 | $103,94132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Georgetown
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Sawsan RashdanDallas$29.9M
- Lucia MasarovaHouston$29.7M
- Jordi Rodon AhnertHouston$28.1M
- Sarina Piha PaulHouston$26M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.